Barry E. Greene - 04 Aug 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Reporting relationship: President and CEO, Director
Issuer ticker: SAGE
Reported as of: 04 Aug 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Aug 2023, 16:15:55 UTC
Prior SEC filing: 25 May 2023
Next SEC filing: 15 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Barry Greene

Key filing fact

Barry E. Greene filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 08 Aug 2023.

Key facts

This page summarizes Barry E. Greene's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Aug 2023, 16:15.

Change

Previous filing in this sequence was filed on 25 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SAGE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +195,000
Change %
Price: $0.000000
Shares after: 195,000
Date: 04 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 195,000
Exercise price: $85.82
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On January 4, 2021, the reporting person was granted an option to purchase 650,000 shares of common stock. The option vests upon the achievement of certain milestones, one of which was met on August 4, 2023, resulting in the vesting of the option as to 195,000 shares.